PhaseV

ML for Clinical Trial Optimization

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in January 2023 by Raviv Pryluk, Dan Goldstaub, and Elad Berkman, PhaseV operates with 11–50 employees. The company has raised $65 million across two funding rounds from six investors. In May 2025, PhaseV secured a Series A funding round led by Accel and Insight Partners.

Business overview

PhaseV develops a platform for adaptive clinical trial design and closed-loop execution, leveraging an intuitive user interface and flexible software architecture. The company utilizes cutting-edge algorithms, including reinforcement learning and causal machine learning, to support key clinical decisions throughout the trial process. PhaseV operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Clinical Workflow solutions.

Strategic signal

In March 2026, PhaseV launched AI Conductor, a centralized platform designed to automate clinical workflows from protocol to submission. This development signals a significant advancement in the company's offering, aiming to streamline complex processes in clinical development and enhance efficiency for pharmaceutical clients and researchers.

Log in to access full profile

Company Intelligence Q&A

What was the most recent significant funding event for PhaseV?
In May 2025, PhaseV completed a Series A funding round, raising $50 million. This round was co-led by Accel and Insight Partners.
What is PhaseV's AI Conductor?
PhaseV launched its AI Conductor in March 2026. This platform automates clinical workflows from protocol design through submission, centralizing and streamlining various stages of clinical development.
Has PhaseV formed any notable partnerships recently?
In May 2025, PhaseV announced a strategic partnership with the Crohn's & Colitis Foundation to advance Inflammatory Bowel Disease (IBD) research using AI/ML-driven clinical development.
What new platform capabilities did PhaseV unveil in 2024?
In September 2024, PhaseV unveiled the latest capabilities of its AdaptV platform, which uses machine learning to improve oncology clinical trials.
When was PhaseV founded and by whom?
PhaseV was founded in January 2023 by co-founders Raviv Pryluk, Dan Goldstaub, and Elad Berkman.
Log in to access full profile